Jasmine H Francis1, Larissa A Habib2, David H Abramson3, Lawrence A Yannuzzi4, Murk Heinemann3, Mrinal M Gounder5, Rachel N Grisham6, Michael A Postow5, Alexander N Shoushtari5, Ping Chi7, Neil H Segal8, Rona Yaeger8, Alan L Ho5, Paul B Chapman5, Federica Catalanotti2. 1. Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill-Cornell Medical Center, New York, New York. Electronic address: francij1@mskcc.org. 2. Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York; Weill-Cornell Medical Center, New York, New York. 4. Vitreous, Retina, Macula Consultants of New York, New York, New York; The LuEsther T. Mertz Retina Research Laboratory, New York, New York. 5. Weill-Cornell Medical Center, New York, New York; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Weill-Cornell Medical Center, New York, New York; Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York. 7. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 8. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
PURPOSE: To investigate the clinical and morphologic characteristics of serous retinal disturbances in patients taking mitogen-activated protein kinase kinase (MEK) inhibitors. PARTICIPANTS: A total of 313 fluid foci in 50 eyes of 25 patients receiving MEK inhibitors for treatment of their metastatic cancer, who had evidence of serous retinal detachments confirmed by optical coherence tomography (OCT). DESIGN: Single-center, retrospective cohort study. METHODS: Clinical examination and OCT were used to evaluate MEK inhibitor-associated subretinal fluid. The morphology, distribution, and location of fluid foci were serially evaluated for each eye. Choroidal thickness was measured at each time point (baseline, fluid accumulation, and fluid resolution). Two independent observers performed all measurements. Statistical analysis was used to correlate interobserver findings and compare choroidal thickness and visual acuity at each time point. MAIN OUTCOME MEASURES: Comparison of OCT characteristics of retinal abnormalities at baseline to fluid accumulation. RESULTS: The majority of patients had fluid foci that were bilateral (92%) and multifocal (77%) and at least 1 focus involving the fovea (83.3%). All fluid foci occurred between the interdigitation zone and an intact retinal pigment epithelium. The 313 fluid foci were classified into 4 morphologies, as follows: 231 (73.8%) dome, 36 (11.5%) caterpillar, 31 (9.9%) wavy, and 15 (4.8%) splitting. Best-corrected visual acuity at fluid resolution was not statistically different from baseline; and no eye lost more than 2 Snellen lines from baseline at the time of fluid accumulation. There was no statistical difference in the choroidal thickness between the different time points (baseline, fluid accumulation, and fluid resolution). A strong positive interobserver correlation was obtained for choroidal thickness measurements (r = 0.97, P < 0.0001) and grading of foci morphology (r = 0.97, P < 0.0001). CONCLUSION: The subretinal fluid foci associated with MEK inhibitors have unique clinical and morphologic characteristics, which can be distinguished from the findings of central serous chorioretinopathy. In this series, MEK inhibitors did not cause irreversible loss of vision or serious eye damage.
PURPOSE: To investigate the clinical and morphologic characteristics of serous retinal disturbances in patients taking mitogen-activated protein kinase kinase (MEK) inhibitors. PARTICIPANTS: A total of 313 fluid foci in 50 eyes of 25 patients receiving MEK inhibitors for treatment of their metastatic cancer, who had evidence of serous retinal detachments confirmed by optical coherence tomography (OCT). DESIGN: Single-center, retrospective cohort study. METHODS: Clinical examination and OCT were used to evaluate MEK inhibitor-associated subretinal fluid. The morphology, distribution, and location of fluid foci were serially evaluated for each eye. Choroidal thickness was measured at each time point (baseline, fluid accumulation, and fluid resolution). Two independent observers performed all measurements. Statistical analysis was used to correlate interobserver findings and compare choroidal thickness and visual acuity at each time point. MAIN OUTCOME MEASURES: Comparison of OCT characteristics of retinal abnormalities at baseline to fluid accumulation. RESULTS: The majority of patients had fluid foci that were bilateral (92%) and multifocal (77%) and at least 1 focus involving the fovea (83.3%). All fluid foci occurred between the interdigitation zone and an intact retinal pigment epithelium. The 313 fluid foci were classified into 4 morphologies, as follows: 231 (73.8%) dome, 36 (11.5%) caterpillar, 31 (9.9%) wavy, and 15 (4.8%) splitting. Best-corrected visual acuity at fluid resolution was not statistically different from baseline; and no eye lost more than 2 Snellen lines from baseline at the time of fluid accumulation. There was no statistical difference in the choroidal thickness between the different time points (baseline, fluid accumulation, and fluid resolution). A strong positive interobserver correlation was obtained for choroidal thickness measurements (r = 0.97, P < 0.0001) and grading of foci morphology (r = 0.97, P < 0.0001). CONCLUSION: The subretinal fluid foci associated with MEK inhibitors have unique clinical and morphologic characteristics, which can be distinguished from the findings of central serous chorioretinopathy. In this series, MEK inhibitors did not cause irreversible loss of vision or serious eye damage.
Authors: Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean Jacques Grob; Vanna Chiarion Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymyr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Michelle Casey; Daniele Ouellet; Anne-Marie Martin; Ngocdiep Le; Kiran Patel; Keith Flaherty Journal: N Engl J Med Date: 2014-09-29 Impact factor: 91.245
Authors: Megan C Turner; Kara Rossfeld; April K S Salama; Douglas Tyler; Georgia Beasley Journal: Expert Opin Pharmacother Date: 2017-03-22 Impact factor: 3.889
Authors: Maryam Fouladi; Clinton F Stewart; Susan M Blaney; Arzu Onar-Thomas; Paula Schaiquevich; Roger J Packer; Stewart Goldman; J Russell Geyer; Amar Gajjar; Larry E Kun; James M Boyett; Richard J Gilbertson Journal: J Neurooncol Date: 2013-07-09 Impact factor: 4.130
Authors: Catherine Y Liu; Jasmine H Francis; Scott E Brodie; Brian Marr; Jose S Pulido; Michael F Marmor; David H Abramson Journal: Retina Date: 2014-07 Impact factor: 4.256
Authors: Akosua A Nti; Leona W Serrano; Harpal S Sandhu; Katherine E Uyhazi; Ilaina D Edelstein; Elaine J Zhou; Scott Bowman; Delu Song; Tara C Gangadhar; Lynn M Schuchter; Sheryl Mitnick; Alexander Huang; Charles W Nichols; Ravi K Amaravadi; Benjamin J Kim; Tomas S Aleman Journal: Retina Date: 2019-03 Impact factor: 4.256
Authors: William Foulsham; Benjeil Z Edghill; O D Julia Canestraro; Vicky Makker; Jason Konner; David H Abramson; Jasmine H Francis Journal: Am J Ophthalmol Case Rep Date: 2022-07-08